Yuhan Corporation announced on the 25th that it will officially launch its personal blood glucose meter, "Yuhan Blood Check," in the domestic market. The product was developed by the domestic medical device manufacturer OSANG Healthcare and will be sold by Yuhan Corporation. "Yuhan Blood Check" enhances the convenience and reliability of the blood glucose meter, a key device for personal health management. It boasts various strengths, including user-friendly design, intuitive indicator functions, and a wide 2.5-inch display, particularly providing intuitive color indicator displays for blood glucose measurement results, allowing elderly users or those unfamiliar with devices to easily understand their health status. Yuhan Corporation plans to actively respond to the self-health management market demand not only for diabetes patients but also for general consumers who are concerned about blood glucose levels through "Yuhan Blood Check." Furthermore, they are exploring the potential for expansion into service areas linked with smart devices such as continuous glucose monitors (CGM) and will continue to strengthen their responsibilities and roles for public health.
PCL announced on the 25th that it has signed a contract to supply the multiple blood screening device HiSU, the portable blood screening device PCLOK Ⅱ, and reagents to ASTA, a specialized diagnostic service company for blood centers in Russia, for five years. ASTA conducts blood screening tests for 3 million blood donors annually at 88 blood centers managing blood in Russia. PCL will produce the products and supply them under its brand, while ASTA will handle local product registration and marketing and distribution. ASTA has decided to replace the equipment and reagents from the U.S. company Abbott currently used in 88 blood centers with PCL's products. Through this contract, PCL expects to generate about 100 billion won in sales over the next ten years.
Dong-A Pharmaceutical announced on the 25th that it will launch a new energy drink product called "Eul Doctor." Eul Doctor has gained great popularity among consumers with its representative honey combination recipe. Modisher, a term combining modify and consumer, refers to proactive consumers who reconfigure existing products into new forms according to their preferences. Eul Doctor contains 1500 mg of taurine and three types of vitamin B, considering fatigue recovery and concentration enhancement. In particular, taurine, which is present in the highest amount, is known for its muscle recovery and detoxification effects, helping remove harmful oxygen.
HLB Global announced on the 25th that it has officially launched an "AI Healthcare Consortium" in collaboration with ACA (Asia Capital Alliance), Japan's largest private equity firm, and leading medical AI corporations. The consortium includes HLB Global, ACA, SELVAS AI, JLK, VUNO, Mediana and others. The consortium aims to connect healthcare data between Korea and Japan and innovate future healthcare paradigms as a strategic turning point, with the goal of realizing personalized medicine and a preventive-centered medical AI system through AI technology.
AptaBio announced on the 25th that it participated in "BIO USA 2025" held in Boston, USA, from June 16-19 (local time), introducing its major pipelines and conducting numerous one-on-one partnering meetings with global pharmaceutical companies for technology transfer and joint development. The company's primary pipelines include the diabetes kidney disease and acute kidney injury treatment drug "APX-115," based on the pan-NOX inhibition mechanism, the oral age-related macular degeneration treatment "ABF-101" based on a non-VEGF mechanism, and the blood cancer treatment "Apta-16" employing aptamer-drug conjugate (Apta-DC) platform technology. Active discussions on technology transfer and joint development centered around APX-115 were held during the event. APX-115 is a first-in-class new drug candidate that inhibits pan-NOX enzymes, and clinical phase 2b has started in Korea for diabetes kidney disease indications. Development is ongoing with the goal of completing patient dosing in the second half of this year.
The clinical specimen analysis institution GCCL announced on the 25th that it has established an analysis method for the bio marker MAO-B (monoamine oxidase B) related to central nervous system (CNS) diseases through a clinical trial consignment contract with NeuroBioGen. MAO-B is known to be an enzyme that breaks down monoamines such as dopamine and regulates the amount of neurotransmitters. Currently, MAO-B inhibitors are used as treatments for Parkinson's disease, and MAO-B is closely related to Alzheimer’s disease, making it applicable in various research settings. The clinical trial consignment project supported by GCCL for NeuroBioGen is a phase 2a clinical trial to evaluate the efficacy and safety of KDS2010 in patients with mild cognitive impairment and mild Alzheimer’s disease dementia.
The telemedicine platform corporation SolDac announced on the 25th that it has signed a memorandum of understanding (MOU) for a cooperative project with the global healthcare company SELVAS Healthcare to collaborate on remote health management solutions, including telemedicine. By integrating data measurement solutions necessary for systematic self-management, such as SELVAS Healthcare's body composition measuring device, blood pressure monitor, and SELVAS AI's AI disease probability prediction service "Selvy Checkup" with SolDac's telemedicine solution, home care and remote health management will be made possible in various residential spaces, from apartments to senior residences and elderly care facilities. Users can utilize telemedicine services linked to the measurement of blood pressure, body composition, and blood glucose, while managers from medical institutions like hospitals and public health centers can efficiently monitor and care for seniors, the company explained.
SYMBOL Healthcare, a company developing AI musculoskeletal digital therapeutics, announced on the 25th that it has received approval for its pivotal clinical trial plan (IDE) for the digital therapy "4DEYE DTx" from the Ministry of Food and Drug Safety. "4DEYE DTx" is a digital therapy that provides customized rehabilitation exercises to patients with chronic knee pain through a non-face-to-face app-based approach. Notably, this approval is exceptional in the musculoskeletal digital therapeutics market as it proceeds directly to pivotal clinical trials without exploratory clinical trials, which is interpreted as a result of the Ministry's high evaluation of the innovation and potential of "4DEYE DTx." The clinical trial will be co-led by Professor Lee Byung-hoon of Gachon University Gil Medical Center's orthopedic department and SYMBOL Healthcare, and will be conducted over approximately six months starting this month.